Tirzepatide

Tirzepatide is a synthetic peptide studied in metabolic research as a dual receptor agonist, activating both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual mechanism is investigated for its combined effect on insulin secretion, glucagon regulation, gastric emptying and appetite signaling.

Its structure includes a C-20 fatty-diacid chain that promotes albumin binding and extends its plasma half-life to roughly 5 days, supporting once-weekly research protocols. Supplied as research-grade material for laboratory use only.

• Dual GIP/GLP-1 receptor pharmacology and signaling
• Glucose homeostasis and insulin secretion studies
• Appetite and satiety modulation research
• Gastric emptying and GI motility research
• Obesity and metabolic disorder research models
• Comparison with single and triple incretin agonists

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Dual GIP/GLP-1 agonist. Start low and titrate up roughly every 4 weeks in research. Do not exceed 15 mg/week.

Reconstitute the 10 mg vial in 2 mL of bacteriostatic water (5 mg/mL). Use the calculator for the exact units for your dose.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.